XHIGM with CD40LG mutations has been classified as combined T and B immunodeficiency, and the overall prognosis of these patients is poor, with an overall survival rate of 20–28.2% [9, 14, 19, 20]. This evidence concerns the gene CD40LG and Immunodeficiency.